Immune-related and Common Adverse Events With Programmed Cell Death 1/Programmed Cell Death Ligand 1 inhibitors combined with other Anticancer Therapy for Solid Tumors: A Systematic Review and Meta-analysis

The combination of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) inhibitors and anticancer therapies has been in the spotlight in recent years. However, the risks associated with these combination therapies are not fully elucidated. The primary objective of this study was to...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical oncology (Royal College of Radiologists (Great Britain)) 2025-01, Vol.37, p.103662, Article 103662
Hauptverfasser:	Inoue, T., Narukawa, M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen - antagonists & inhibitors Humans Immune checkpoint inhibitor Immune Checkpoint Inhibitors - adverse effects Immune Checkpoint Inhibitors - therapeutic use immune-related adverse events Neoplasms - drug therapy PD-1 inhibitor PD-L1 inhibitor Programmed Cell Death 1 Receptor - antagonists & inhibitors Solid tumors systematic review
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!